Liquid and Solid Potassium Chloride: Bioavailability and Safety

Skoutakis, Vasilios A.; Acchiardo, Sergio R.; Wojciechowski, Norbert J.; Carter, Charles A.

doi:10.1002/j.1875-9114.1984.tb03402.x

Cited by 5 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have confirmed that the bioavailability of PS and MEC and MET, as assessed by percentage urinary excretion, was equivalent (4,13). However, significantly greater amounts of potassium chloride were excreted in the first 2 h after administration of MEC or MET.…”

Section: Introductionmentioning

confidence: 77%

What is the better formulation of microencapsulated potassium chloride?

Simoneau

Bergmann

Pamphile

et al. 1994

Eur. J. Drug Metab. Pharmacokinet.

View full text Add to dashboard Cite

A single blind cross-over study was performed comparing a new microencapsulated potassium chloride tablet (MET) with two reference formulations of oral potassium, namely potassium chloride solution (PS), and microencapsulated potassium chloride capsules (MEC), in 18 normal healthy volunteers. The potassium chloride induced change in gastric potential difference (PD) of the mucosa was the main criterion of comparison and was assessed by the area above curve (AAC), the total duration of the effect (TDE), the maximal variation of PD (delta MAX), and the aggression index (AI). The results showed that all three formulations induced a fall in PD; the delta MAX and AAC were significantly greater for PS indicating a higher aggressive effect of the solution; MET had significantly less aggressive effect than MEC when assessed by all parameters.

show abstract

Section: Introductionmentioning

confidence: 77%

What is the better formulation of microencapsulated potassium chloride?

Simoneau

Bergmann

Pamphile

et al. 1994

Eur. J. Drug Metab. Pharmacokinet.

View full text Add to dashboard Cite

show abstract

In vitro and in vivo assessment of the bioavailability of potassium from a potassium tartrate tablet

Whiting

Gorecki

Jones

1991

Biopharm & Drug Disp

View full text Add to dashboard Cite

The bioavailability of potassium from orally administered potassium tartrate was evaluated in 20 normal subjects under metabolic balance conditions. Subjects were given 34 mmol potassium (5 tablets of Cal-K) as a divided dose on each of 2 consecutive days. Urinary excretion of potassium, as determined from 24-h urinary collections on the 3 days preceding dosage totalled 192.6 +/- 50.9 mmol (mean +/- S.D., n = 20). It increased significantly (p less than 0.05) to 258.7 +/- 54.2 mmol for the 2 days of dosage and the following day. The difference of 66.1 mmol representing absorbed potassium was close to the 68 mmol potassium given and indicated a bioavailability of potassium in excess of 97 per cent; after correction for creatinine excretion, potassium recovery rose to 99.9 per cent. The dissolution characteristics of the Cal-K tablets were also determined. After dissolution in simulated gastric juice (pH 1.2), 84.4 +/- 10.6 per cent (mean +/- S.D., 6 experiments) was dissolved; after adjustment to pH 7.3, dissolved potassium increased to 91.3 +/- 8.5 per cent. No precipitation or residue formed as a result of the pH change. Both sets of results indicate that potassium from these potassium tartrate tablets is in a highly bioavailable form.

show abstract

Miscellaneous drugs and agents

Dukes¹

1986

Side Effects of Drugs Annual

View full text Add to dashboard Cite

Liquid and Solid Potassium Chloride: Bioavailability and Safety

Cited by 5 publications

References 12 publications

What is the better formulation of microencapsulated potassium chloride?

What is the better formulation of microencapsulated potassium chloride?

In vitro and in vivo assessment of the bioavailability of potassium from a potassium tartrate tablet

Miscellaneous drugs and agents

Contact Info

Product

Resources

About